Keywords
programmed chemotherapy
complications
myelosuppression
How to Cite
Abstract
Acute leukemia is a rapidly progressing hematological malignancy that requires intensive programmed chemotherapy as the main treatment approach. Despite significant advances in modern chemotherapeutic protocols, treatment is often associated with a wide range of complications, including myelosuppression, infectious complications, cardiotoxicity, hepatotoxicity, and metabolic disturbances. Early diagnosis and timely correction of these adverse effects are essential for improving treatment outcomes and patient survival. This article reviews the main complications of modern programmed chemotherapy in acute leukemia, discusses diagnostic approaches for early detection, and outlines current strategies for their correction and management. Emphasis is placed on a multidisciplinary approach to minimize treatment-related toxicity while maintaining therapeutic efficacy.
References
1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. New England Journal of Medicine. 2021;384: 208–224.
2. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review. Blood Cancer Journal. 2017;7(6):e577.
3. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. 2024.
4. European Society for Medical Oncology (ESMO). AML Clinical Practice Guidelines. 2023.
5. Kantarjian H, et al. Chemotherapy toxicity in acute leukemia. Journal of Clinical Oncology. 2020.
6. DeAngelo DJ. Treatment of acute leukemia and complications. Hematology/Oncology Clinics. 2019
7. Estey EH. Acute myeloid leukemia management. The Lancet. 2018;392: 102–112.
8. Freifeld AG, et al. Clinical practice guideline for fever and neutropenia. Clinical Infectious Diseases. 2011 (updated recommendations used widely).
9. Lipshultz SE, et al. Anthracycline cardiotoxicity in cancer therapy. Circulation. 2013;128: 869–879.
10. World Health Organization (WHO). Cancer treatment guidelines and supportive care in oncology. 2023.
